This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the US in January.

For over a decade, Humira has been the highest-grossing drug in the world, bringing in some $21 billion for manufacturer AbbVie in 2021. Humira is a versatile drug used to treat multiple ...

Highlights from "Deadline: White House." ...